| Ytd | -92.92% | |
| 1y | -94.98% |
| Open | 1.32 | Prev Close | 1.32 | Low | 1.31 | High | 1.32 | Mkt Cap | 3.42M |
| Vol | 13.62K | Avg Vol | 311.91K | EPS | -37.04 | P/E | N/A | Forward P/E | -1.57 |
| Beta | 1.33 | Short Ratio | 0.88 | Inst. Own | 2.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.87 | 200-d Avg | 8.95 | 1yr Est | 6.25 |
CLDI News
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-mark
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.94) per share. This is a 47.74 p
Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the curren
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-sta
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Ca
Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark
SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“C
Crown Holdings Inc (CCK) stock gained 16.4% in pre-market trading after reporting strong Q2 results
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 25.1% to $3.79 during Monday&
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company"
SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Cal
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a bi
SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Ca
SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Ca
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnolog
IND enabling studies with CLD-401 to continue with IND submission targeted by end of 2026 as Calidi
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Ca
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Cal
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Cal
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(0.43) per share which beat the ana
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Cali
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Antonio F. Santidrian, PhD, Chief Scientific Officer and
CLD-401 is the lead candidate from the Company's RedTail platform, a systemically delivered viro
SAN DIEGO, April 29, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“C
Shares of Bed Bath & Beyond (BBBY) rose 23.4% in pre-market trading after beating revenue estima
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnolog
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“C
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a bi
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Ca
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnolog
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a bi
SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“C
$12 Million of Tranche Warrants Potential Financing Within One Year From Closing $12 Million of Tran
U.S. stocks fall on Friday with the S&P 500 and NASDAQ dropping around 1%. Energy shares rise wh
Stocks down, Nasdaq falls 300+ points. Dow down 1.62%, Nasdaq down 1.47%, S&P 500 down 1.38%. En
10,519,631 units, with each unit consisting of one share of common stock (or pre-funded warrant in l
Short Term Tranche Warrants Potentially Raise $10.4 Million within 12 months of Closing Short Term T
Calidi Biotherapeutics shares plunged after hours following a public offering announcement, trading
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnolog
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnolog
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.21) per share which missed the a
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a cl
On October 27, 2025, Calidi Biotherapeutics, Inc. (the "Company") entered into that certain
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-sta